eEF2K沉默联合丹参酮ⅡA磺酸钠协同抑制人肺腺癌细胞系A549增殖

doi:10.16352/j.issn.1001-6325.2022.01.017

基础医学与临床 ›› 2022, Vol. 42 ›› Issue (1): 106-113.doi: 10.16352/j.issn.1001-6325.2022.01.017

eEF2K沉默联合丹参酮ⅡA磺酸钠协同抑制人肺腺癌细胞系A549增殖

王布, 袁胜芳, 张长洪, 苑程, 黄攀登, 张志华, 赵建清^*

河北北方学院附属第一医院呼吸内科, 河北张家口 075000

收稿日期:2020-11-09 修回日期:2021-05-15 出版日期:2022-01-05 发布日期:2022-01-05
通讯作者: ^* whkj86@163.com
基金资助:
河北省卫生厅科研基金(20180818);张家口市科技攻关计划(1712008D)

Silencing eEF2K combined with sodium tanshinone ⅡA sulfonate synergistically inhibit proliferation of human lung adenocarcinoma cell line A549

WANG Bu, YUAN Sheng-fang, ZHANG Chang-hong, YUAN Cheng, HUANG Pan-deng, ZHANG Zhi-hua, ZHAO Jian-qing^*

Department of Respiratory Medicine, the First Affiliated Hospital of Hebei Northern College, Zhangjiakou 075000, China

Received:2020-11-09 Revised:2021-05-15 Online:2022-01-05 Published:2022-01-05
Contact: ^* whkj86@163.com

摘要/Abstract

摘要： 目的探讨真核延伸因子2激酶(eEF2K)基因转染及丹参酮ⅡA磺酸钠(STS)对肺腺癌细胞系A549增殖、侵袭和迁移的影响及其机制。方法预实验筛选STS最佳作用浓度。将A549细胞分为siRNA-NC组(转染siRNA-NC)、siRNA-eEF2K组(转染siRNA-eEF2K)、siRNA-NC+STS组(转染siRNA-NC+10 μg/mL STS)和siRNA-eEF2K+STS组(转染siRNA-eEF2K+10 μg/mL STS)。CCK-8法、克隆形成实验、Transwell小室法、划痕实验和流式细胞测量术检测细胞存活率、克隆形成率、穿膜细胞数、迁移率和凋亡率;免疫印迹法(Western blot)检测蛋白激酶B(AKT)、磷酸化(p)-AKT、Ki67、基质金属蛋白酶2(MMP-2)和B淋巴细胞瘤-2基因(Bcl-2)蛋白表达。结果与siRNA-NC组比较,siRNA-eEF2K组、siRNA-NC+STS组和siRNA-eEF2K+STS组细胞存活率、克隆形成率、穿膜细胞数、迁移率和p-AKT、Ki67、MMP-2、Bcl-2蛋白均明显降低,细胞凋亡率明显升高(P＜0.05),且siRNA-eEF2K+STS组中上述指标变化幅度最大。结论 eEF2K沉默联合STS可协同抑制A549细胞增殖,其作用机制可能与抑制p-AKT、Ki67、MMP-2、Bcl-2蛋白表达有关。

关键词: 肺腺癌, 真核延伸因子激酶-2, 丹参酮ⅡA磺酸钠, 增殖, 侵袭

Abstract: Objective To investigate the effects of eukaryotic elongation factor-2 kinase (eEF2K) gene transfection and sodium tanshinone Ⅱ A sulfonate (STS) on proliferation, invasion and migration of lung adenocarcinoma cell line A549 and its mechanism. Methods The optimal concentration of STS was screened out by preliminary experiment. A549 cells were divided into siRNA-NC group (transfected with siRNA-NC), siRNA-eEF2K group (transfected with siRNA-eEF2K), siRNA-NC+STS group (treated with 10 μg/mL STS after siRNA-NC) and siRNA-eEF2K+STS group (treated with 10 μg/mL STS after siRNA-eEF2K).The survival rate, clone formation, cell counting of transmembrane cells, migration and apoptosis of A549 cells were detected by CCK-8 method, clone formation test, Transwell chamber test, scratch test and flow cytometry. The protein expression levels of protein kinase B (AKT), phosphorylation (p)-AKT, Ki67, matrix metalloproteinase-2 (MMP-2) and B-cell lymphoma-2 genes (Bcl-2) were detected by Western blot. Results Compared with those in siRNA-NC group, the cell survival rate, clone formation rate, number of transmembrane cells, migration rate and p-AKT, Ki67, MMP-2 and Bcl-2 in proteins siRNA-eEF2K+STS group were significantly lower, while the apoptosis rate was significantly higher (P＜0.05). The siRNA-eEF2K+STS group had the largest range of changes in the above indexes. Conclusions Silencing eEF2K combined with STS can synergistically inhibit the proliferation, invasion and migration of A549 cells and promote cell apoptosis. The mechanism is potentially related to the inhibition of protein expression of p-AKT, Ki67, MMP-2 and Bcl-2.

Key words: lung adenocarcinoma, eukaryotic elongation factor 2 kinase, sodium tanshinone ⅡA sulfonate, proliferation, invasion

中图分类号:

R734.2

王布, 袁胜芳, 张长洪, 苑程, 黄攀登, 张志华, 赵建清. eEF2K沉默联合丹参酮ⅡA磺酸钠协同抑制人肺腺癌细胞系A549增殖[J]. 基础医学与临床, 2022, 42(1): 106-113.

WANG Bu, YUAN Sheng-fang, ZHANG Chang-hong, YUAN Cheng, HUANG Pan-deng, ZHANG Zhi-hua, ZHAO Jian-qing. Silencing eEF2K combined with sodium tanshinone ⅡA sulfonate synergistically inhibit proliferation of human lung adenocarcinoma cell line A549[J]. Basic & Clinical Medicine, 2022, 42(1): 106-113.

参考文献

[1]付丹阳, 张捷. 肺腺癌诊断的研究进展[J]. 中国实验诊断学, 2019, 23:172-174.
[2]肖婷, 刘锐, 王明伟. 癌症治疗的新靶点——eEF2K[J]. 生命的化学, 2016, 36:397-403.
[3]Xie J, Shen K, Lenchine RV, et al. Eukaryotic elonga-tion factor 2 kinase upregulates the expression of proteins implicated in cell migration and cancer cell metastasis[J]. Int J Cancer, 2018, 142:1865-1877.
[4]杨渊, 陈楠, 马千里, 等. 阿帕替尼联合大剂量丹参酮ⅡA对肺腺癌A549细胞株凋亡及Bim异构体的影响[J]. 现代肿瘤医学, 2019, 27:1319-1323.
[5]王琳, 胡凯文, 迟佳琪, 等. 丹参酮ⅡA磺酸钠联合顺铂对小鼠lewis肺癌细胞上皮性钙黏蛋白表达的影响[J]. 环球中医药, 2018, 11:22-26.
[6]Zhu HC, Song HM, Chen GZ, et al. eEF2K promotes progression and radioresistance of esophageal squamous cell carcinoma[J]. Radiother Oncol, 2017, 124:439-447.
[7]张岚, 赵玉倩, 刘博. 新型的eEF2K抑制剂BL-EKI03在乳腺癌中诱导自噬和凋亡作用机制研究[J]. 中国药理学与毒理学杂志, 2016, 30:1063.
[8]Xie J, Liu JH, Liu H, et al. Tanshinone ⅡA combined with adriamycin inhibited malignant biological behaviors of NSCLC A549 cell line in a synergistic way[J]. BMC Cancer, 2016, 16:1-14.
[9]谢琼, 曾柏荣, 何欣. 丹参酮ⅡA对TP治疗NSCLC临床疗效的影响[J]. 现代肿瘤医学, 2015, 23:341-343.
[10]Liao SY, Kuo IY, Chen YT, et al. AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression[J]. Oncogene, 2019, 38:1-14.
[11]Lu M, Liu B, Xiong H, et al. Trans-3,5,4'-trimethoxystilbene reduced gefitinib resistance in NSCLCs via suppressing MAPK/Akt/Bcl-2 pathway by upregulation of miR-345 and miR-498[J]. J Cell Mol Med, 2019, 23:2431-2441.
[12]Li H, Zhao J, Jia X, et al. miR-21 promotes growth, invasion and migration of lung cancer cells by AKT/P-AKT/cleaved-caspase 3/MMP-2/MMP-9 signaling pathway[J]. Int J Clin Exp Patho, 2020, 13:692-700.
[13]Karakaᶊ D, Ozpolat B. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target[J]. J Mol Med, 2020, 98:775-787.
[14]肖敏, 王根柱, 戚欣, 等. eEF2K对MDA-MB-231细胞增殖的影响与初步机制研究[J]. 中国药理学通报, 2018, 34:1061-1065.
[15]Wang R, Luo Z, Zhang H, et al. Tanshinone ⅡA reverses gefitinib-resistance in human non-small-cell lung cancer via regulation of VEGFR/Akt pathway[J]. Onco Targets Ther, 2019, 7:9355-9365.

eEF2K沉默联合丹参酮ⅡA磺酸钠协同抑制人肺腺癌细胞系A549增殖

Silencing eEF2K combined with sodium tanshinone ⅡA sulfonate synergistically inhibit proliferation of human lung adenocarcinoma cell line A549

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	刘磊, 李世宝, 张好良. 沉默lnc-SLC2A12-10:1抑制人胃癌细胞系AGS增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(7): 1071-1076.
[2]	康有力, 赵丹, 杜文静, 李莉. SIRT5通过调控ALDH5A1的琥珀酰化促进人乳腺癌细胞的增殖[J]. 基础医学与临床, 2022, 42(7): 1099-1107.
[3]	白冰, 张海芳, 杨庆良, 秦悦, 周晨龙, 宋歌, 王颖. 下调lncRNA RHPN1-AS1抑制人膀胱癌细胞系T24增殖和迁移[J]. 基础医学与临床, 2022, 42(6): 940-944.
[4]	杜雪梅, 张运梅, 周文婷, 吕宏. miR-655-3p靶向KIF20A抑制人肺腺癌细胞系A549迁移及侵袭[J]. 基础医学与临床, 2022, 42(4): 599-606.
[5]	孙全鹏, 樊超, 展德玺, 范怡明, 孙伟峰. 罗哌卡因抑制人肝癌细胞系Hep3B增殖、迁移和侵袭[J]. 基础医学与临床, 2022, 42(3): 448-453.
[6]	张健, 张吉炯. LncRNA UNC5B-AS1靶向miR-339-5p调控人肺腺癌细胞系A549增殖和凋亡[J]. 基础医学与临床, 2022, 42(3): 454-460.
[7]	杨芒庄, 杨旭东, 王晓龙. Circ-MALAT1靶向miR-101抑制膀胱癌细胞系SW780侵袭和迁移[J]. 基础医学与临床, 2022, 42(3): 472-478.
[8]	刘新兵, 张美红. 钩吻碱通过下调circ_001680抑制类风湿关节炎滑膜成纤维细胞增殖和侵袭[J]. 基础医学与临床, 2022, 42(3): 429-435.
[9]	赵霞, 蔡庆春, 丁瑞敏, 张倩. 华蟾素抑制人鼻咽癌细胞系CNE2和HONE1增殖[J]. 基础医学与临床, 2022, 42(3): 436-440.
[10]	陈茜, 刘宪, 崔南, 翟阳. 敲除EZH2抑制人宫颈癌细胞系迁移和侵袭[J]. 基础医学与临床, 2022, 42(3): 395-400.
[11]	张春利, 齐结华, 宦宇, 吴守乐, 蔡徐山. 干扰ADAM17抑制人宫颈癌细胞系HeLa细胞增殖[J]. 基础医学与临床, 2022, 42(2): 255-259.
[12]	李勇晓, 孙燕, 张瑞生. 丙泊酚抑制人子宫内膜癌细胞系RL95-2增殖[J]. 基础医学与临床, 2022, 42(1): 114-119.
[13]	王灵霞, 严玉兰, 袁海涛, 蔡烨伟, 刘德慧, 谷文露, 曹碧月. CircRNA_23113抑制肺腺癌细胞的增殖和迁移[J]. 基础医学与临床, 2022, 42(1): 82-88.
[14]	史铁伟, 李天柱, 周静, 娜日苏, 孙琪, 许丽艳, 白春英. 5-脂氧合酶激活蛋白抑制剂MK886对人食管癌细胞系增殖和凋亡的影响[J]. 基础医学与临床, 2022, 42(1): 56-61.
[15]	刘晓玉施萍潘伯臣庞希宁. 人羊膜间充质干细胞无血清培养方法的建立[J]. 基础医学与临床, 2021, 41(8): 1181-1185.